Literature DB >> 911371

Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid.

L A Carlson, M Danielson, I Ekberg, B Klintemar, G Rosenhamer.   

Abstract

In an ongoing study 558 consecutive survivors of myocardial infarction below 70 years, mean age 59 years, were randomly allocated 4 months after the acute episode into a control group or a chemotherapy group from December 1972 to April 1976. Both groups were given moderate advice about diet and the chemotherapy group was prescribed clofibrate, 1 g twice daily, and nicotinic acid 1 g three times daily. Serum cholesterol and triglycerides were lowered around 15-20% and 30% respectively in the chemotherapy group while only insignificant reductions were observed in the control group. Until December 1976 total mortality and mortality from IHD has been the same in the two groups. The number of non-fatal myocardial infarctions has been 38 in the control and 19 in the chemotherapy group, a statistically significant reduction (P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911371     DOI: 10.1016/0021-9150(77)90201-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

Review 1.  Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-06       Impact factor: 9.546

2.  Lipid lowering drugs: what is their place in therapeutics?

Authors:  L Simons
Journal:  Drugs       Date:  1979-06       Impact factor: 9.546

3.  Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis.

Authors:  I Holme
Journal:  Br Heart J       Date:  1993-01

Review 4.  Dietary prevention of ischaemic heart disease--a policy for the '80s.

Authors:  B Lewis
Journal:  Br Med J       Date:  1980-07-19

Review 5.  Drug Therapy of Dyslipidemia in the Elderly.

Authors:  Srikanth Yandrapalli; Shashvat Gupta; Gabriela Andries; Howard A Cooper; Wilbert S Aronow
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

6.  Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.

Authors:  P Grützmacher; E H Scheuermann; W Siede; P D Lang; U Abshagen; H W Radtke; C A Baldamus; W Schoeppe
Journal:  Klin Wochenschr       Date:  1986-10-01

7.  Recognition and management of hypercholesterolaemia in patients awaiting elective coronary artery bypass grafting.

Authors:  G Asimakopoulos; C Barlow; R Pillai
Journal:  Postgrad Med J       Date:  1998-03       Impact factor: 2.401

Review 8.  Antiplatelet drugs: clinical pharmacology and therapeutic use.

Authors:  A S Gallus
Journal:  Drugs       Date:  1979-12       Impact factor: 9.546

9.  Women in the POSCH trial. Effects of aggressive cholesterol modification in women with coronary heart disease. The POSCH Group. Program on the Surgical Control of the Hyperlipidemias.

Authors:  H Buchwald; C T Campos; J P Matts; L L Fitch; J M Long; R L Varco
Journal:  Ann Surg       Date:  1992-10       Impact factor: 12.969

Review 10.  Hypothesis into theory--the development of aetiological concepts of ischaemic heart disease: a review.

Authors:  B Lewis
Journal:  J R Soc Med       Date:  1978-11       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.